DBVT News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

DB

Mkt Cap

$568.5M

Volume

523.56K

Next Earnings

October 27th

Loading chart

DB

DBVTDBV Technologies S.A. American Depositary Shares

DBVT

Pay with—

Available Balance0.00

DB

Mkt Cap

$568.8M

Volume

523.56K

Next Earnings

October 27th

Chart Financials Earnings News About Insider Filings

DBV Technologies annonce le dépôt de sa demande de licence biologique (BLA) auprès de la Food and Drug Administration des Etats-Unis pour le patch VIASKIN® Peanut destiné aux enfants âgés de 4 à 7 ans.DBV Technologies announced the submission of a Biologics License Application (BLA) to the FDA for its VIASKIN® Peanut patch, designed to treat peanut allergies in children aged 4-7 years. The application is based on positive results from the Phase 3 VITESSE clinical trial, the largest immunotherapy study conducted in this patient population, involving 654 children. DBV has requested priority review of the BLA.GlobeNewswire Inc. · Sep 29, 2026

DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 YearsDBV Technologies submitted a Biologics License Application (BLA) to the FDA for VIASKIN® Peanut Patch, a non-invasive epicutaneous immunotherapy treatment for peanut allergies in children aged 4-7 years. The submission is supported by positive results from the VITESSE Phase 3 clinical trial involving 654 children, the largest immunotherapy trial for this population. DBV has requested Priority Review status.GlobeNewswire Inc. · Sep 29, 2026

Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 août 2026DBV Technologies announced the sale of approximately $50 million of American Depositary Shares (ADSs) through its At-The-Market (ATM) program on Nasdaq. The company had previously filed an ATM prospectus for up to $150 million in sales.GlobeNewswire Inc. · Sep 2, 2026

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of August 31, 2026DBV Technologies announced the sale of approximately $50 million of American Depositary Shares (ADSs) through its At-The-Market (ATM) program on Nasdaq. The company had previously filed an ATM prospectus for up to $150 million in sales. As of August 31, 2026, the company had 314,388,807 total shares outstanding.GlobeNewswire Inc. · Sep 2, 2026

DBV Technologies annonce le placement d’ADS pour un montant d’environ 50 millions de Dollars US dans le cadre de son programme At-The-Market (ATM) sur le NasdaqDBV Technologies announced the placement of approximately $50 million in American Depositary Shares (ADS) with RA Capital Management through its At-The-Market (ATM) program on Nasdaq. The company will issue 18.288 million new ordinary shares at $13.67 per ADS, representing a 5.82% dilution to existing shareholders. The transaction is expected to close on August 3, 2026.GlobeNewswire Inc. · Jul 30, 2026

DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on NasdaqDBV Technologies announced the sale of approximately $50 million in American Depositary Shares (ADSs) through its At-The-Market program on Nasdaq. The company issued 18,288,220 new ordinary shares (3,657,644 ADSs) at $13.67 per ADS to RA Capital Management through Citizens JMP Securities. The issuance represents a 5.82% dilution to existing shareholders and is expected to close on August 3, 2026.GlobeNewswire Inc. · Jul 30, 2026

DBV Technologies dépose un prospectus relatif à son Programme At-The-Market (ATM) pour un montant pouvant atteindre 150 millions de dollarsDBV Technologies has filed a new S-3ASR registration statement with the SEC to renew its at-the-market (ATM) offering program for up to $150 million in American Depositary Shares (ADSs). The company plans to use proceeds primarily for manufacturing capacity expansion, pediatric BLA submissions for peanut allergy treatment, and product development. The program was established with Citizens JMP Securities as the placement agent.GlobeNewswire Inc. · Jul 17, 2026

DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for FilingDBV Technologies announced it has completed extensive discussions with the FDA regarding its Biologics License Application (BLA) for the VIASKIN® Peanut Patch in children aged 4-7 years. The FDA did not request additional data, but DBV will incorporate feedback on data organization and formatting before submitting the BLA in Q3 2026.GlobeNewswire Inc. · Jun 29, 2026

DBV Technologies fait le point sur le dépôt du dossier BLA pour le patch VIASKIN® Peanut chez les enfants âgés de 4 à 7 ans; la Société travaille en collaboration avec la FDA afin d'optimiser le processus d'examen en vue du dépôt du dossierDBV Technologies announced it has completed in-depth discussions with the FDA regarding the Biologics License Application (BLA) for VIASKIN® Peanut patch for children aged 4-7 years. The FDA did not request additional data, and DBV plans to submit the BLA in Q3 2026 after incorporating FDA feedback on data organization and structuring for CMC and biostatistical elements.GlobeNewswire Inc. · Jun 29, 2026

DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare ConferenceDBV Technologies announced that CEO Daniel Tassé will not participate in the previously scheduled fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, due to unavoidable travel disruption. The company will still participate in 1-on-1 investor meetings at the event in Miami, FL.GlobeNewswire Inc. · Jun 9, 2026

to start trading

DB

DBVTDBV Technologies S.A. American Depositary Shares

DBVT

Pay with—

Available Balance0.00

Your PositionYou don't own any DBVT yet.

Related Tickers

Earnings